Libtayo 350 mg/7 mL (50 mg/mL) injection Images

Generic Name: cemiplimab

This medication has been identified as Libtayo 350 mg/7 mL (50 mg/mL) injection. It is supplied by Regeneron Pharmaceuticals, Inc.

Libtayo is used in the treatment of Squamous Cell Carcinoma; Non Small Cell Lung Cancer; Basal Cell Carcinoma and belongs to the drug class anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors). Libtayo 350 mg/7 mL (50 mg/mL) injection is not a controlled substance under the Controlled Substances Act (CSA).

Images of medication

Libtayo

Generic Name

cemiplimab

Strength

350 mg/7 mL (50 mg/mL) injection

Availability

Prescription only

Drug Class

Anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)

CSA Schedule

Not a controlled drug

Labeler / Supplier

Regeneron Pharmaceuticals, Inc.

National Drug Code (NDC)

61755-0008

Drug Uses Add to Drug List Print

Get help with Imprint Code FAQs.

See also:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer